Not Yet RecruitingNot Applicable

SAfety and eFfectiveness of cathetER Ablation for Atrial Fibrillation With Intracerebral Hemorrhage (SAFER-AF)

China646 participantsStarted 2026-01

Plain-language summary

SAFER-AF is an investigator-initiated, multicenter, open-label, parallel-group trial comparing catheter ablation versus usual care in patients with atrial fibrillation and intracerebral hemorrhage.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥ 18 years
✓. Between 14 Days and 12 Months After Spontaneous Intracerebral Hemorrhage
✓. Able to Access Intracerebral Hemorrhage Imaging Data
✓. ECG indicating the presence of atrial fibrillation
✓. CHA₂DS₂-VA Score ≥ 2
✓. Willing to undergo randomization and able to complete follow-up as required

Exclusion criteria

✕. Atrial fibrillation secondary to clearly reversible causes (e.g., hyperthyroidism, hypokalemia, etc.)
✕. Fully dependent (modified Rankin Scale \[mRS\] score \> 4)
✕. Uncontrolled hypertension (systolic blood pressure \> 160 mmHg)
✕. Presence of uncontrolled active bleeding
✕. Presence of active infection requiring antibiotic treatment
✕. End-stage renal failure or receiving dialysis treatment
✕. Presence of liver failure
✕. Untreated coronary artery disease with indication for revascularization

What they're measuring

Composite of All-Cause Mortality, All-Cause Stroke, and Systemic Embolism

Timeframe: 48 months

Trial details

NCT IDNCT07316270

SponsorBeijing Anzhen Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2030-01

Contact for this trial

Liu He

13810720787 theliu@139.com

View on ClinicalTrials.gov More AF - Atrial Fibrillation trials